Selank and Semax are both peptides that evidence suggests modulate brain connectivity and are found in cognitive-enhancing preparations. Selank has been investigated for its potential anxiolytic effects, even in the presence of neurodegeneration, and its impact on anxiety in Parkinson's disease models. Semax, on the other hand, has shown promise in enhancing neurological recovery in ischemic stroke patients and reducing stress-induced anxiety and depression in preclinical models. Both peptides appear to influence brain networks, suggesting roles in neurological and psychiatric contexts, with some evidence pointing to their presence in the illicit supply chain of cognitive enhancers.
| Selank | Semax | |
|---|---|---|
| Drug class | nootropic, anxiolytic | nootropic |
| Studies in corpus | 74 | 74 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | other · 23 rct · 2 preclinical animal · 38 in vitro · 6 review · 1 cohort · 1 | preclinical animal · 51 other · 10 review · 2 in vitro · 8 rct · 1 |
| Studies with explicit sample size | 5 | 3 |
| Head-to-head studies in corpus | 3 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Selank and Semax batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 740 Selank batches across 476 manufacturers, 99.66% avg purity.
We tested 809 Semax batches across 528 manufacturers, 99.38% avg purity.
We hold deeper lab coverage on Semax (809 batches tested). Selank edges ahead on average measured purity (99.66% vs 99.38%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Selank and Semax — the gold-standard direct comparison evidence.
This research highlights the potential of Selank as a therapeutic agent for managing non-motor symptoms, specifically anxiety, in Parkinson's disease, even in the presence of significant neurodegeneration. The fact that its anxiolytic effect persists despit…
The analysis successfully identified multiple instances of various putative cognitive enhancing research peptides within the seized preparations. Specifically, well-known compounds such as Noopept, Semax, and Selank were consistently detected across a signi…
This research provides crucial insights into the neurobiological mechanisms underlying the known anxiolytic and nootropic effects of Selank and Semax. Understanding how these peptides modulate specific brain networks could pave the way for more targeted the…
No direct head-to-head trials in our corpus. Indirect comparison only. While both peptides alter brain connectivity, their specific therapeutic focuses appear to diverge based on the studies indexed here. Selank's anxiolytic effect has been noted in Parkinson's disease models, suggesting a mechanism independent of direct dopaminergic system repair. Semax, in contrast, has demonstrated efficacy in improving neurological recovery in ischemic stroke patients and reducing stress-induced anxiety and depression in preclinical animal models. The corpus also contains a review highlighting peptide bioregulators, including Semax, for age-related neurological conditions and cognitive decline. The evidence for Selank includes a comparative review of GABA-targeting sedatives, though its specific mechanism within that context is not detailed here. Both peptides have been identified in seized preparations, indicating their presence in the illicit market for cognitive enhancers.
Looking for vendor-level purity, endotoxin, and HPLC data on Selank or Semax? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.